ORPHA:623
NAME syndrome
Also known as: Nevi-atrial myxoma-myxoid neurofibromata-ephelides syndrome
Publications
1,341,065
Trials
0
Interventional, condition-specific
Researchers
459
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,341,065 matched papers (852,302 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,341,065
1,341,065 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,341,065 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
852,302 in the last 10 years · low confidence
Phrase hits: 75 · MeSH hits: 0
Who's working on it?
459
Distinct author names in 75 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Happle R2 papers · 2009Papers in Europe PMC
- 02Li P2 papers · 2025
Kaifeng Hospital of Traditional Chinese Medicine, Henan, China.
Papers in Europe PMC - 03Liu Y2 papers · 2025
Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Papers in Europe PMC - 04Seward JB2 papers · 1987Papers in Europe PMC
- 05Tajik AJ2 papers · 1987Papers in Europe PMC
- 06van Haelst MM2 papers · 2022
Department of Human Genetics and Amsterdam Reproduction & Development research institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. m.vanhaelst@amsterdamumc.nl.
Papers in Europe PMC - 07Vidaillet HJ Jr2 papers · 1987Papers in Europe PMC
- 08Wu L2 papers · 2021
Institute of Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, China. chaimen0725@yeah.net.
Papers in Europe PMC - 09Wu M2 papers · 2020
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Papers in Europe PMC - 10Xu J2 papers · 2023
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China. xujianpingmedsci@163.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN33436648·Recruiting·The study aims to investigate the effect of the level of probiotic K12 content on enhancing children's immunity and reducing the frequency of their occurrence of diseases such as pharyngitis, tonsillitis, and rhinitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89448306·Recruiting·Investigating infection risk and the microbiome in blood cancer patients treated with CD19 CAR-T therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN69516953·Not yet recruiting·Protection against invasive non-typhoidal salmonella disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83576037·No longer recruiting·A phase 2, safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy study of a subcutaneous injection of BC-006 and tirzepatide in adults with obesity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN96463686·No longer recruiting·An online psychoeducational and support program implementing ketogenic metabolic therapy for mental illness
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN96250868·Recruiting·Gene therapy study to assess the safety, tolerability and effectiveness of AXV-101 when injected into the eye in patients with a mutated BBS1 gene to prevent sight loss
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26415952·Recruiting·A Study to evaluate novel KarX and KarT Prototypes versus the KarXT and KarX-EC reference following single doses, and to explore the effect of food after multiple doses of selected prototypes in healthy adult participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16516753·No longer recruiting·Can a nebulized medication reduce death rates in adults with severe lung failure on ventilators?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14537646·No longer recruiting·A pilot community outreach intervention with digital health coaching for the prevention of cardiometabolic diseases in socioeconomically disadvantaged neighbourhoods in Uppsala, Sweden
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30482473·No longer recruiting·A Phase II study to understand the safety and effects of inhaled SNG001, the study medication, in patients who are mechanically ventilated due to a respiratory viral infection in the lungs
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99654100·No longer recruiting·A first-in-human phase I/II study to evaluate the safety, tolerability, anti-cancer activity and metabolism of SN38-SPL9111 (DEP®-SN38), an SN38 dendrimer conjugate, in patients with advanced solid tumours.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN34027276·Recruiting·Improving outcomes by addressing variation at the end of routine care for young adults born with cleft lip and/or palate
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30709760·Recruiting·A randomised trial comparing two current ventilation treatments in the Intensive Care Unit: The UK NAVA Trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN93834662·No longer recruiting·The beneficial effect on gastrointestinal discomfort and intestinal function of a dietary supplement based on a probiotic blend, fructooligosaccharides, chamomile extract, and B vitamins in patients with irritable bowel syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15046526·Recruiting·A platform trial for patients with relapsed malignant mesothelioma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18175685·No longer recruiting·Stratification of clinically vulnerable people for COVID-19 risk using antibody testing
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83433606·No longer recruiting·Qishen Yiqi Dripping Pills improve cardiopulmonary function in post-percutaneous coronary intervention patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10047986·Recruiting·Pain-relieving plaster for the treatment of knee osteoarthritis: a multi-center, randomized, positive drug parallel-controlled clinical trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11688703·No longer recruiting·Examining lymph node cells to assess how age affects immune responses
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14544863·No longer recruiting·Feasibility of exercise to improve insulin sensitivity in postmenopausal women who are overweight or obese receiving chemotherapy for breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN75393382·No longer recruiting·Effectiveness and tolerability of Sucrosomial® Iron supplementation in preterm or critically ill infants admitted to Special Neonatal Care Unit
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10736175·No longer recruiting·A study comparing the bioavailability of a taste-masked delafloxacin powder for oral suspension with the delafloxacin tablet in healthy adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97679658·No longer recruiting·A study of a new vaccine against Marburg virus in adults aged 18–55 years
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN71362981·No longer recruiting·A pneumococcal human challenge study in adults aged 50-84 years
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17328380·No longer recruiting·A Phase 1, Open-Label, Drug-Drug Interaction (DDI) Study to Assess the Effect of ASN51 on the Pharmacokinetics of a CYP3A4 Probe Substrate in Healthy Subjects
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for NAME syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("NAME syndrome" OR "Nevi-atrial myxoma-myxoid neurofibromata-ephelides syndrome") OR ("NAME" OR "NAME-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"NAME syndrome" OR "Nevi-atrial myxoma-myxoid neurofibromata-ephelides syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low
Ingested 2026-07-26T14:36:02.094Z
